Variable treatment response to lumasiran in pediatric patients with primary hyperoxaluria type 1
There was a variable response to lumasiran in PH 1. Despite a reduction of hyperoxaluria in many patients with PH 1, only one patient reached normal values and 2 of 8 patients did not respond. Regular monitoring of urinary oxalate values and registry data collection seems mandatory to monitor the efficacy and the long-term outcome of PH 1 treated with lumasiran.
Authors
- M. Rohmann
- Anja Büscher (ORCID: https://orcid.org/0000-0001-5582-0557)
- Katja Doerry (ORCID: https://orcid.org/0000-0001-8184-3592)
- Sebastian Loos (ORCID: https://orcid.org/0000-0002-8620-042X)
- Matthias Hansen
- Kay Latta
- Nele Kanzelmeyer (ORCID: https://orcid.org/0000-0002-4865-4906)
- Sina Saffe
- Markus J. Kemper
Institutions
- Universität Hamburg (DE)
- Medizinische Hochschule Hannover (DE)
- Bürgerhospital Frankfurt am Main (DE)
- University Medical Center Hamburg-Eppendorf (DE)
- Essen University Hospital (DE)
- Jena University Hospital (DE)
- Zentrum für Kinderheilkunde (DE)
- Asklepios Kliniken Hamburg (DE)
Publication Details
- Journal
- Pediatric Nephrology
- Published
- 2025-01-27
- DOI
- https://doi.org/10.1007/s00467-025-06665-w
- Citations
- 7
- Primary Topic
- Kidney Stones and Urolithiasis Treatments
- Type
- article
- Field-Weighted Citation Impact
- 10.63